Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based a Mapping Algorithm Derived from a Chinese Population
media
posted on 2021-04-07, 09:02 authored by Adis journalson behalf of, Tan Chongqing, Li Sini, Yi Lidan, Zeng Xiaohui, Peng Liubao, Qin Shuxia, Wang Liting, Wan Xiaomin<p> </p>
<p><strong>Article full
text</strong></p>
<p> </p>
<p><br></p>
<p> </p>
<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.</p>
